Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
National Institute for Health and Clinical Excellence
Record ID 32011000061
English
Authors' recommendations:
NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. If, after doing this, organisations still wish to consider the use of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma, they should follow the advice set out in ‘Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance' (www.dh.gov.uk/en/DH_064983) which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/nicemedia/live/13255/51332/51332.pdf
Year Published:
2010
URL for published report:
http://www.nice.org.uk/TA207
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Lymphoma, Mantle-Cell
- Recurrence
- Sirolimus
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.